Compare HZO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | REPL |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.0M | 721.7M |
| IPO Year | 1998 | 2018 |
| Metric | HZO | REPL |
|---|---|---|
| Price | $23.61 | $10.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $34.00 | $12.00 |
| AVG Volume (30 Days) | 378.2K | ★ 2.1M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,309,288,000.00 | N/A |
| Revenue This Year | $4.01 | N/A |
| Revenue Next Year | $4.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.85 | $2.68 |
| 52 Week High | $33.45 | $14.80 |
| Indicator | HZO | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 69.07 |
| Support Level | $22.49 | $9.35 |
| Resistance Level | $25.43 | $11.26 |
| Average True Range (ATR) | 1.27 | 0.62 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 49.38 | 65.04 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.